KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Cash Flow (2016 - 2025)

Nektar Therapeutics has reported Net Cash Flow over the past 16 years, most recently at -$25.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$25.9 million for Q4 2025, down 283.67% from a year ago — trailing twelve months through Dec 2025 was -$29.1 million (down 424.56% YoY), and the annual figure for FY2025 was -$29.1 million, down 424.56%.
  • Net Cash Flow for Q4 2025 was -$25.9 million at Nektar Therapeutics, down from -$2.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for NKTR hit a ceiling of $42.8 million in Q1 2022 and a floor of -$98.3 million in Q3 2021.
  • Median Net Cash Flow over the past 5 years was -$3.7 million (2025), compared with a mean of -$9.2 million.
  • Biggest five-year swings in Net Cash Flow: crashed 3870.23% in 2021 and later soared 333.81% in 2022.
  • Nektar Therapeutics' Net Cash Flow stood at -$28.8 million in 2021, then surged by 38.91% to -$17.6 million in 2022, then tumbled by 68.61% to -$29.7 million in 2023, then surged by 147.59% to $14.1 million in 2024, then crashed by 283.67% to -$25.9 million in 2025.
  • The last three reported values for Net Cash Flow were -$25.9 million (Q4 2025), -$2.0 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.